OncoC4 Reveals Initial Participant with Late-Stage Prostate Cancer Receives Dose in Early to Mid-Stage Study for BNT316/ONC-392, a Collaborative Effort with BioNTech.

Absci Begins Preclinical Studies on ABS-101, a New Leading Candidate for an Anti-TL1A Antibody, Created and Enhanced with Advanced AI Design Tools.

STORM Therapeutics will showcase research on its innovative METTL1 tRNA Methyltransferase blockers at the ESMO event for specialized cancer treatments.

FDA hastens assessment of a new application for Linvoseltamab, aimed at treating recurring or resistant forms of Multiple Myeloma.

ReCode Therapeutics Reports Initial Dosing of Subjects in Phase 1 Trial for Inhaled mRNA Therapy, RCT2100, Aimed at Cystic Fibrosis Treatment.

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development has initiated dosing in the early-stage ALETA-001 clinical study, targeting individuals with recurrent or unresponsive B-cell cancers.

FDA has sanctioned a biweekly administration of TECVAYLI® (teclistamab-cqyv) as a therapeutic option for those suffering from recurring or unresponsive multiple myeloma.

The experimental biosimilar by Polpharma Biologics demonstrates similar pharmacokinetics and dynamics to the top-selling IBD medication, Entyvio®.

Voyager Therapeutics Announces Promising Early-Stage Results for Gene Therapy Aimed at Attenuating Tau in Alzheimer's, Pushes Project into Later Research Phase.

Immune-Onc Therapeutics Discloses a Partnership for Clinical Research, Assessing IO-108 in an International Early Phase Trial Aimed at Initial Therapy for Progressive Hepatic Carcinoma.

Monopar Approved to Initiate Initial Human Stage 1 Study of Experimental Radiotherapeutic MNPR-101-Zr for Progressive Cancer Cases.

The FDA has granted Mabwell authorization to proceed with their new ADC targeting B7-H3, referred to as 7MW3711 under an Investigational New Drug application.